CO2023007677A2 - Derivados de pyrazolo[1,5-a]pirazina como inhibidores de la btk - Google Patents
Derivados de pyrazolo[1,5-a]pirazina como inhibidores de la btkInfo
- Publication number
- CO2023007677A2 CO2023007677A2 CONC2023/0007677A CO2023007677A CO2023007677A2 CO 2023007677 A2 CO2023007677 A2 CO 2023007677A2 CO 2023007677 A CO2023007677 A CO 2023007677A CO 2023007677 A2 CO2023007677 A2 CO 2023007677A2
- Authority
- CO
- Colombia
- Prior art keywords
- pyrazolo
- btk inhibitors
- pyrazine derivatives
- formula
- pyrazine
- Prior art date
Links
- 229940124291 BTK inhibitor Drugs 0.000 title 1
- CMGKRWOBNPTZBW-UHFFFAOYSA-N pyrazolo[1,5-a]pyrazine Chemical class C1=NC=CN2N=CC=C21 CMGKRWOBNPTZBW-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se proporcionan compuestos de Fórmula (I'): (I'), o sales farmacéuticamente aceptables de los mismos, en donde las variables en la fórmula son como se definen en la presente y métodos para su uso y producción.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063113515P | 2020-11-13 | 2020-11-13 | |
PCT/US2021/059168 WO2022104079A1 (en) | 2020-11-13 | 2021-11-12 | Pyrazolo[1,5-a]pyrazine derivatives as btk inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2023007677A2 true CO2023007677A2 (es) | 2023-09-08 |
Family
ID=78828007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2023/0007677A CO2023007677A2 (es) | 2020-11-13 | 2023-06-13 | Derivados de pyrazolo[1,5-a]pirazina como inhibidores de la btk |
Country Status (14)
Country | Link |
---|---|
US (1) | US20240083900A1 (es) |
EP (1) | EP4244223A1 (es) |
JP (1) | JP2023549360A (es) |
KR (1) | KR20230119134A (es) |
CN (1) | CN116783199A (es) |
AR (1) | AR124048A1 (es) |
AU (1) | AU2021377891A1 (es) |
BR (1) | BR112023009116A2 (es) |
CL (1) | CL2023001367A1 (es) |
CO (1) | CO2023007677A2 (es) |
MX (1) | MX2023005626A (es) |
TW (1) | TW202233624A (es) |
UY (1) | UY39517A (es) |
WO (1) | WO2022104079A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023086575A1 (en) * | 2021-11-12 | 2023-05-19 | Biogen Ma Inc. | Btk inhibitors |
WO2023220049A1 (en) * | 2022-05-10 | 2023-11-16 | Biogen Ma Inc. | Crystalline polymorphs of n-methyl-n-((1s,3s)-3-methyl-3-((6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl)acrylamide |
WO2024083111A1 (zh) * | 2022-10-18 | 2024-04-25 | 首药控股(北京)股份有限公司 | 一种新型杂环化合物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140228349A1 (en) * | 2011-10-12 | 2014-08-14 | Array Biopharma Inc. | 5,7-substituted-imidazo[1,2-c]pyrimidines |
AU2014296261B2 (en) * | 2013-07-31 | 2018-11-15 | Merck Patent Gmbh | Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof |
WO2015157955A1 (en) * | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Heterocyclic btk inhibit ors |
WO2020114487A1 (en) * | 2018-12-07 | 2020-06-11 | Sunshine Lake Pharma Co., Ltd. | Ret inhibitors, pharmaceutical compositions and uses thereof |
-
2021
- 2021-11-12 BR BR112023009116A patent/BR112023009116A2/pt unknown
- 2021-11-12 CN CN202180089379.6A patent/CN116783199A/zh active Pending
- 2021-11-12 KR KR1020237019845A patent/KR20230119134A/ko unknown
- 2021-11-12 AR ARP210103131A patent/AR124048A1/es unknown
- 2021-11-12 TW TW110142205A patent/TW202233624A/zh unknown
- 2021-11-12 MX MX2023005626A patent/MX2023005626A/es unknown
- 2021-11-12 WO PCT/US2021/059168 patent/WO2022104079A1/en active Application Filing
- 2021-11-12 JP JP2023528245A patent/JP2023549360A/ja active Pending
- 2021-11-12 EP EP21823425.0A patent/EP4244223A1/en active Pending
- 2021-11-12 US US18/036,853 patent/US20240083900A1/en active Pending
- 2021-11-12 AU AU2021377891A patent/AU2021377891A1/en active Pending
- 2021-11-12 UY UY0001039517A patent/UY39517A/es unknown
-
2023
- 2023-05-11 CL CL2023001367A patent/CL2023001367A1/es unknown
- 2023-06-13 CO CONC2023/0007677A patent/CO2023007677A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
MX2023005626A (es) | 2023-07-31 |
CN116783199A (zh) | 2023-09-19 |
TW202233624A (zh) | 2022-09-01 |
CL2023001367A1 (es) | 2024-01-05 |
WO2022104079A1 (en) | 2022-05-19 |
KR20230119134A (ko) | 2023-08-16 |
BR112023009116A2 (pt) | 2023-10-03 |
AU2021377891A9 (en) | 2024-04-18 |
AR124048A1 (es) | 2023-02-08 |
EP4244223A1 (en) | 2023-09-20 |
AU2021377891A1 (en) | 2023-07-06 |
US20240083900A1 (en) | 2024-03-14 |
UY39517A (es) | 2022-06-30 |
JP2023549360A (ja) | 2023-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2023007677A2 (es) | Derivados de pyrazolo[1,5-a]pirazina como inhibidores de la btk | |
CO2022006858A2 (es) | Inhibidores de pequeñas moléculas de mutante g12c de kras | |
ECSP056246A (es) | DERIVADOS DE PIRROLO [3,4-c]PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA | |
CO2021006114A2 (es) | Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento del cáncer | |
CO2022001357A2 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
CO2021002651A2 (es) | Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met | |
CO2022001094A2 (es) | Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas | |
CO2021016594A2 (es) | Pirroles tricíclicos condensados como moduladores de alfa-1 antitripsina | |
AR050694A1 (es) | Dihidropteridinonas para el tratamiento de enfermedades oncologicas | |
CR7880A (es) | Derivados sustituidos de pirrolo-pirazol como inhibidores de quinasa | |
CY1116880T1 (el) | ΠΑΡΑΓΩΓΑ ΙΜΙΔΑΖΟ[2,1-b][1,3,4]ΘΕΙΑΔΙΑΖΟΛΗΣ | |
UY29420A1 (es) | Derivados de 2-piridona,composiciones que los contienen, procesos de preparación y aplicación | |
UY28738A1 (es) | Deridos 1h-tieno(2,3-c)pirazol útiles como inhibidores de quinasa | |
NI201000143A (es) | Derivados bicíclicos heterocíclicos o espirobicíclicos heterocíclicos enlazados, de pirazolo[1,5-a] pirimidinas, procedimientos para su preparación y usos de los mismos. | |
UY28695A1 (es) | Derivados de difenilazetidona | |
AR083751A1 (es) | Derivados de 1h-pirrolo[2,3-b]piridina y uso de los mismos en el tratamiento del cancer | |
CO2021013166A2 (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria | |
UY39193A (es) | Compuestos de azalactama como inhibidores de hpk1 | |
CL2022000093A1 (es) | Imidazopirimidinas como inhibidores de eed y uso de estas | |
CL2022000955A1 (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 | |
UY28356A1 (es) | Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos | |
CL2019001023A1 (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia. | |
CO2021014155A2 (es) | Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2 | |
AR015518A1 (es) | Uso de derivados de tiadiazolo piridina para la produccion de un medicamento para el tratamiento de enfermedades que se modulan mediante la inhibicion delas fosfodiesterase(s) | |
UY39475A (es) | Compuestos útiles para la preparación de pirazolopirimidinonas |